From Animal Models to Patient Samples: The Regulatory Rise of Functional Assays under the FDA Modernization Act 2.0
The FDA’s regulatory shift away from animal testing has opened new avenues for preclinical innovation. Functional assays using native patient samples now offer a clinically translatable, ethical alternative for early drug evaluation. Learn how this paradigm is being implemented at Vivia Biotech to bridge discovery and clinical development.